InxMed FAK Inhibitor Ifebemtinib Received Breakthrough Therapy Designation by China National Medical Products Administration for First-Line Non-Small Cell Lung Cancer (NSCLC) with KRAS G12C Mutation

InxMed translates unmet medical need into breakthrough product. Rooted in disease biology driven translational research, we develop innovative therapies targeting essential survival mechanism of tumors.
InxMed have invented a highly differentiable portfolio of novel therapeutics against full nodes in tumor defense, expanding from cell membrane to nucleus, with modalities of small molecule, antibody and ADC. The target breadth and therapeutic modalities enable us to pursue fundamental solutions to improved efficacy and prolong survival in patients with a variety of cancer types.
Rationalized combo is a must to win the battle against cancers. InxMed aims to invent regimen which is highly efficacious but safer. It is only possible to achieve such goal via partnership. We actively seek co-development and strategic business development opportunities, especially clinical combination and licensing of inhibitors of RAS pathway and ADCs. We aim to invent revolutionary, breakthrough therapies based on deep insights of underlying disease biology.
We invent personalized medicines with global impact, and turn innovation in China to life saving therapies for the world
Tel: +86 25-58251030
Email: office@inxmed.com
Office address: 73 Tanmi Road Block D-2, 3rd Floor Jiangbei New District, Nanjing
Follow Us:
CopyRight © 2022 InxMed All Rights Reserved.